BR112015021448A2 - kits e métodos para o tratamento de câncer utilizando peptídeos gliadina - Google Patents

kits e métodos para o tratamento de câncer utilizando peptídeos gliadina

Info

Publication number
BR112015021448A2
BR112015021448A2 BR112015021448A BR112015021448A BR112015021448A2 BR 112015021448 A2 BR112015021448 A2 BR 112015021448A2 BR 112015021448 A BR112015021448 A BR 112015021448A BR 112015021448 A BR112015021448 A BR 112015021448A BR 112015021448 A2 BR112015021448 A2 BR 112015021448A2
Authority
BR
Brazil
Prior art keywords
administering
kits
methods
patient
treating cancer
Prior art date
Application number
BR112015021448A
Other languages
English (en)
Other versions
BR112015021448B1 (pt
Inventor
L Shaw Fred
Original Assignee
Barmarsa Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barmarsa Res Llc filed Critical Barmarsa Res Llc
Publication of BR112015021448A2 publication Critical patent/BR112015021448A2/pt
Publication of BR112015021448B1 publication Critical patent/BR112015021448B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "kits e métodos para o tratamento de câncer utilizando peptídeos gliadina". kits e métodos para tratar câncer compreendendo a administração de um peptídeo gliadina a um paciente são aqui revelados. um kit de acordo com a invenção compreende uma composição farmacêutica compreendendo um peptídeo gliadina e instruções para administrar o peptídeo a um paciente. o kit pode ainda compreender uma composição farmacêutica compreendendo pelo menos um agente quimioterápico como um inibidor do receptor da tirosinaquinase e instruções para coadministrar os compostos. um método de tratamento do câncer de acordo com a invenção compreende administrar um peptídeo gliadina a um paciente e pode ainda compreender coadministrar pelo menos um agente quimioterápico como um inibidor do receptor de tirosinaquinase. a coadministração de um peptídeo gliadina e receptor de tirosinaquinase a um paciente com câncer é eficaz para reduzir ou impedir a resistência do câncer ao inibidor do receptor da tirosina quinase.
BR112015021448-7A 2013-03-07 2014-03-07 Uso do peptídeo gliadina no tratamento de câncer BR112015021448B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774285P 2013-03-07 2013-03-07
US61/774,285 2013-03-07
PCT/US2014/021660 WO2014138556A1 (en) 2013-03-07 2014-03-07 Kits and methods for the treatment of cancer using gliadin peptides

Publications (2)

Publication Number Publication Date
BR112015021448A2 true BR112015021448A2 (pt) 2017-10-10
BR112015021448B1 BR112015021448B1 (pt) 2022-04-19

Family

ID=50483486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021448-7A BR112015021448B1 (pt) 2013-03-07 2014-03-07 Uso do peptídeo gliadina no tratamento de câncer

Country Status (15)

Country Link
US (2) US9254308B2 (pt)
EP (1) EP2964242B1 (pt)
JP (1) JP6352952B2 (pt)
KR (1) KR102230514B1 (pt)
CN (2) CN105120881A (pt)
AU (1) AU2014225496B2 (pt)
BR (1) BR112015021448B1 (pt)
CA (1) CA2903471C (pt)
DK (1) DK2964242T3 (pt)
HK (1) HK1212920A1 (pt)
IL (1) IL241230B (pt)
MX (1) MX370858B (pt)
NZ (1) NZ711682A (pt)
SG (1) SG11201506963UA (pt)
WO (1) WO2014138556A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312810B (zh) * 2017-07-11 2020-10-09 南开大学 酶催化苯丁酸氮芥-多肽水凝胶的制备及抗癌应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729296B1 (fr) * 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
WO2003053332A2 (en) 2001-08-20 2003-07-03 Myriad Genetics, Inc Composition and method for treating viral infection
JP2004099459A (ja) * 2002-09-05 2004-04-02 Asama Chemical Co Ltd 抗腫瘍剤
AU2003266376A1 (en) 2003-09-01 2005-03-16 Galapagos Genomics N.V. Polypeptides and polynucleotides for use as a medicament
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
AU2011295919A1 (en) * 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
WO2014002108A1 (en) * 2012-06-27 2014-01-03 Amrita Vishwa Vidyapeetham University A core-shell nanostructure on the basis of proteins with corresponding therapeutic agents

Also Published As

Publication number Publication date
IL241230A0 (en) 2015-11-30
AU2014225496A1 (en) 2015-09-24
EP2964242A1 (en) 2016-01-13
CN105120881A (zh) 2015-12-02
IL241230B (en) 2021-02-28
AU2014225496B2 (en) 2018-03-15
KR102230514B1 (ko) 2021-03-19
US9254308B2 (en) 2016-02-09
CN118217382A (zh) 2024-06-21
DK2964242T3 (en) 2019-03-04
US20140256647A1 (en) 2014-09-11
US9669068B2 (en) 2017-06-06
JP2016529202A (ja) 2016-09-23
WO2014138556A1 (en) 2014-09-12
KR20150138230A (ko) 2015-12-09
US20160143991A1 (en) 2016-05-26
JP6352952B2 (ja) 2018-07-04
CA2903471C (en) 2022-11-01
CA2903471A1 (en) 2014-09-12
MX370858B (es) 2020-01-08
EP2964242B1 (en) 2018-11-14
NZ711682A (en) 2021-07-30
SG11201506963UA (en) 2015-10-29
MX2015011833A (es) 2016-06-02
HK1212920A1 (zh) 2016-06-24
BR112015021448B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
EA201792304A1 (ru) Комбинированная терапия для лечения рака
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
EA201692470A1 (ru) Фармацевтические комбинации
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
WO2015035410A8 (en) Cancer therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS.